Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances
Schizophrenia significantly limits social functioning with positive and negative symptoms and cognitive dysfunction. Blonanserin (LONASEN®), a novel second-generation antipsychotic approved for treating schizophrenia in Japan in 2008, reportedly shows beneficial effects on cognitive function as well...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2021-01-01
|
| סדרה: | Journal of Pharmacological Sciences |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S1347861320300967 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|